Poster display Poster Display session

147P - Clinicopathological significance of HER2 and EGFR expression in urothelial carcinoma: A single center study

Presentation Number
147P
Lecture Time
17:10 - 17:10
Speakers
  • Gulrukh K. Botiralieva (Tashkent, UZ)
Session Name
Poster display
Location
Foyer La Scene, Paris Marriott Rive Gauche, Paris, France
Date
05.03.2018
Time
17:10 - 18:00
Authors
  • Gulrukh K. Botiralieva (Tashkent, UZ)
  • Mirzagaleb Tillyashaykhov (Tashkent, UZ)
  • Abrorjon Yusupbekov (Tashkent, UZ)

Abstract

Background

Urinary bladder cancer is the ninth most common malignancy in the Uzbekistan. 94% cases of urinary bladder cancer made up urothelial carcinoma (UC). There were limited options for patients who are refractory to systemic chemotherapy. Targeted agents as EGFR/HER2 has been proved in a wide range of cancers, but no studies have yet clarified the clinicopathological significance of them in UC. The aim of this study is determination of EGFR/HER2 overexpression which would widen therapeutic options for patients with advanced UC.

Methods

We collected 48 consecutive cystectomy specimens with muscle-invasive urothelial carcinomas from patients with stage T2-4N0-1M1 seen at National Cancer Research Center of Uzbekistan from 2001 to 2003, who had available clinical follow up. Immunohistochemical expression of these molecules was assessed retrospectively in all of these patients, as well as associations between the expression of these molecules and clinicopathological factors or clinical outcome.

Results

The proportions of positive cases for EGFR and HER2 overexpression were 29.3 and 2.3%, respectively. Clinicopathologically, EGFR overexpression was associated with macroscopic type (P=0.0124), lymph node metastasis (P=0.0008), tumour stage (P=0.0422), lymphatic vessel invasion (P=0.0381), and perineural invasion (P=0.0359). Median survival for Her-2/neu and EGFR positive primary tumors was 29 and 35 months, compared with 53 and 49 months for Her-2/neu and EGFR negative cases (P = 0.46), retrospectively. Similarly, Her-2/neu overexpression in the lymph node metastasis did not predict survival.

Conclusions

EGFR and Her-2/neu overexpression may be necessary to accurately determine Her-2/neu and EGFR status in metastatic bladder urothelial carcinoma. EGFR expression is associated with clinical factors involved in tumor progression and invasion, whereas Her-2/neu overexpression in primary or metastatic tumor did not predict survival in this cohort of muscle-invasive tumors. Our results suggest the validity and significance of molecular targeting agents for EGFR and Her-2/neu pathways, and that further preclinical and clinical studies are warranted for improving the clinical outcome of UC.

Legal entity responsible for the study

National Cancer Research Center of Uzbekistan

Funding

Has not received any funding

Disclosure

All authors have declared no conflicts of interest.

Collapse